ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Anterogen.Co.Ltd (065660.KQ)
Anterogen.Co.Ltd stock price today, ATLAS forecast and fair value
Healthcare · Pharmaceuticals · KOSDAQ · South Korea
₩13,980▼ -2.31%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Anterogen.Co.Ltd in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Anterogen.Co.Ltd
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Anterogen.Co.Ltd a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩12,689 and ₩15,224; in 9 out of 10, between ₩10,798 and ₩17,891. Estimated annual volatility is 47%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩134B
- Market cap (USD)
- $101M
- 52-week high
- ₩61,800
- 52-week low
- ₩13,390
- Revenue (12 months)
- ₩7.5B
- Gross margin
- 50.9%
- Operating margin
- -54.5%
- Net margin
- -85.6%
- Beta
- 0.47
What this means
ATLAS does not publish a fair value for 065660.KQ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 065660.KQ has traded between ₩13,390 and ₩61,800. Today it is 77.4% below that high and 4% above its low.
Its beta is 0.47: it tends to move less than the market.
About the company
,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally.
Want to see everything about Anterogen.Co.Ltd?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Anterogen.Co.Ltd do?
,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally.
What is the chance 065660.KQ goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, 065660.KQ ends the month between ₩12,689 and ₩15,224.
How big is Anterogen.Co.Ltd and what is its P/E ratio?
Anterogen.Co.Ltd's market capitalization is ₩134B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 065660.KQ?
ATLAS estimates annual volatility at 47%. In a typical month, half of the outcomes end between ₩12,689 and ₩15,224.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer